Nasdaq · CIK 0001601830
RXRX RECURSION PHARMACEUTICALS, INC.
Insider trading from SEC Form 4. Last filing 5 d ago. Close $4.36 on Oct 9, 2026, +54% from the 52-week low and -36% from the high.
Last 90 days
Net insider value
-$546k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
4
$546k by 3 insiders
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
RXRXOct 9, 2026 · close 4.36
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at RECURSION PHARMACEUTICALS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 16Weak | Blake Borgeson director sell | $242k 50,000 shares | -1% | +63% from low-32% from high | |
| 3Weak | Robert Hershberg director sell | $125k 25,000 shares | -13% | +63% from low-32% from high | |
| 22Weak | Najat Khan CEO and President sell | $79k 22,408 shares | -1% | - | |
| 13Weak | Blake Borgeson director sell | $100k 30,000 shares | -0% | - | |
| 23Weak | Christopher Gibson Chief Executive Officer sell | $476k 100,000 shares | -9% | +17% from low-57% from high | |
| 22Weak | Christopher Gibson Chief Executive Officer sell | $471k 100,000 shares | -9% | +14% from low-58% from high | |
| 31Weak | Christopher Gibson Chief Executive Officer sell | $484k 100,000 shares | -9% | +22% from low-56% from high | |
| 35Weak | Najat Khan Chief R&D Commercial Officer sell | $202k 36,599 shares | -5% | +39% from low-49% from high | |
| 48Moderate | Christopher Gibson Chief Executive Officer sell | $3.3M 618,175 shares | -41% | +33% from low-51% from high | |
| 33Weak | Christopher Gibson Chief Executive Officer sell | $837k 138,574 shares | -11% | - | |
| 18Weak | Christopher Gibson Chief Executive Officer sell | $259k 40,000 shares | -3% | - | |
| 19Weak | Christopher Gibson Chief Executive Officer sell | $316k 40,000 shares | -3% | - | |
| 19Weak | Christopher Gibson Chief Executive Officer sell | $287k 40,000 shares | -5% | - | |
| 19Weak | Christopher Gibson Chief Executive Officer sell | $286k 40,000 shares | -5% | - | |
| 34Weak | Christopher Gibson Chief Executive Officer sell | $302k 40,000 shares | -5% | - | |
| 19Weak | Blake Borgeson director sell | $87k 11,447 shares | -0% | - | |
| 15Weak | Michael Secora Chief Financial Officer sell | $230k 30,000 shares | -2% | - | |
| 18Weak | Blake Borgeson director sell | $77k 11,447 shares | -0% | - | |
| 0Weak | Tina Marriott President and COO sell | $38k 6,000 shares | -1% | - | |
| 11Weak | Blake Borgeson director sell | $76k 11,447 shares | -0% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Robert Hershberg director | MOption exercise Class A Common Stock10b5-1 | +25,000 | $2.22 | $56k | 187,156 | 5 d ago |
| Oct 6, 2026 | Blake Borgeson director | SOpen-market sale Class A Common Stock10b5-1 | -50,000 | $4.84 | $242k | 6,108,287 | 5 d ago |
| Oct 6, 2026 | Robert Hershberg director | SOpen-market sale Class A Common Stock10b5-1 | -25,000 | $5.00 | $125k | 162,156 | 5 d ago |
| Oct 6, 2026 | Robert Hershberg director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $2.22 | $56k | 500,000 | 5 d ago |
| Oct 1, 2026 | Dean Y Li director | AGrant or award Class A Common Stock | +3,378 | $0.00 | $0 | 1,476,707 | 10 d ago |
| Oct 1, 2026 | Zavain Dar director | AGrant or award Class A Common Stock | +4,607 | $0.00 | $0 | 245,371 | 10 d ago |
| Sep 15, 2026 | Ben R Taylor Chief Financial Officer | FTax withholding Class A Common Stock | -5,396 | $3.41 | $18k | 1,071,462 | 26 d ago |
| Sep 8, 2026 | Najat Khan CEO and President | SOpen-market sale Class A Common Stock10b5-1 | -22,408 | $3.52 | $79k | 2,072,890 | 32 d ago |
| Sep 1, 2026 | Blake Borgeson director | SOpen-market sale Class A Common Stock10b5-1 | -30,000 | $3.34 | $100k | 6,158,287 | 40 d ago |
| Sep 25, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class A Common Stock10b5-1 | +100,000 | $0.00 | $0 | 1,054,229 | Sep 26, 2025 |
| Sep 25, 2025 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stock10b5-1 | -100,000 | $4.76 | $476k | 954,229 | Sep 26, 2025 |
| Sep 25, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class B Common Stockderivative10b5-1 | -0 | $0.00 | $0 | 5,253,034 | Sep 26, 2025 |
| Sep 10, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class A Common Stock10b5-1 | +120,000 | $0.00 | $0 | 1,074,229 | Sep 12, 2025 |
| Sep 10, 2025 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stock10b5-1 | -100,000 | $4.71 | $471k | 974,229 | Sep 12, 2025 |
| Sep 10, 2025 | Christopher Gibson Chief Executive Officer | GGift Class A Common Stock10b5-1 | -20,000 | $0.00 | $0 | 954,229 | Sep 12, 2025 |
| Sep 10, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class B Common Stockderivative10b5-1 | -120,000 | $0.00 | $0 | 5,253,034 | Sep 12, 2025 |
| Aug 26, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class A Common Stock10b5-1 | +100,000 | $0.00 | $0 | 1,054,229 | Aug 28, 2025 |
| Aug 26, 2025 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stock10b5-1 | -100,000 | $4.84 | $484k | 954,229 | Aug 28, 2025 |
| Aug 26, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class B Common Stockderivative10b5-1 | -100,000 | $0.00 | $0 | 5,373,034 | Aug 28, 2025 |
| Aug 15, 2025 | Najat Khan Chief R&D Commercial Officer | FTax withholding Class A Common Stock | -3,789 | $5.64 | $21k | 704,796 | Aug 19, 2025 |
| Aug 15, 2025 | Christopher Gibson Chief Executive Officer | FTax withholding Class A Common Stock | -40,390 | $5.64 | $228k | 954,229 | Aug 19, 2025 |
| Aug 18, 2025 | Najat Khan Chief R&D Commercial Officer | SOpen-market sale Class A Common Stock | -36,599 | $5.52 | $202k | 668,197 | Aug 19, 2025 |
| Aug 11, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class A Common Stock10b5-1 | +423,666 | $0.00 | $0 | 1,504,919 | Aug 13, 2025 |
| Aug 11, 2025 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stock10b5-1 | -500,300 | $5.28 | $2.6M | 1,004,619 | Aug 13, 2025 |
| Aug 11, 2025 | Christopher Gibson Chief Executive Officer | GGift Class A Common Stock10b5-1 | -10,000 | $0.00 | $0 | 994,619 | Aug 13, 2025 |
| Aug 11, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class A Common Stockindirect: by LAHWRAN-3 LLC10b5-1 | +100,000 | $0.00 | $0 | 100,000 | Aug 13, 2025 |
| Aug 11, 2025 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stockindirect: by LAHWRAN-3 LLC10b5-1 | -100,000 | $5.28 | $528k | 0 | Aug 13, 2025 |
| Aug 11, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class A Common Stockindirect: by Gibson Family Trust10b5-1 | +17,875 | $0.00 | $0 | 17,875 | Aug 13, 2025 |
| Aug 11, 2025 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stockindirect: by Gibson Family Trust10b5-1 | -17,875 | $5.28 | $94k | 0 | Aug 13, 2025 |
| Aug 11, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class B Common Stockderivative10b5-1 | -423,666 | $0.00 | $0 | 5,473,034 | Aug 13, 2025 |
| Aug 11, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class B Common Stockderivativeindirect: by LAHWRAN-3 LLC10b5-1 | -100,000 | $0.00 | $0 | 386,000 | Aug 13, 2025 |
| Aug 11, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class B Common Stockderivativeindirect: by Gibson Family Trust10b5-1 | -17,875 | $0.00 | $0 | 50,000 | Aug 13, 2025 |
| Jul 1, 2025 | Zavain Dar director | AGrant or award Class A Common Stock | +2,924 | $0.00 | $0 | 135,817 | Jul 3, 2025 |
| Jun 18, 2025 | Blake Borgeson director | AGrant or award Class A Common Stock | +22,016 | $0.00 | $0 | 7,089,863 | Jun 23, 2025 |
| Jun 18, 2025 | Namandje Bumpus director | AGrant or award Class A Common Stock | +11,008 | $0.00 | $0 | 47,557 | Jun 23, 2025 |
| Jun 18, 2025 | Zavain Dar director | AGrant or award Class A Common Stock | +22,016 | $0.00 | $0 | 132,893 | Jun 23, 2025 |
| Jun 18, 2025 | Robert Hershberg director | AGrant or award Class A Common Stock | +22,016 | $0.00 | $0 | 73,732 | Jun 23, 2025 |
| Jun 18, 2025 | Dean Y Li director | AGrant or award Class A Common Stock | +22,016 | $0.00 | $0 | 1,234,618 | Jun 23, 2025 |
| Jun 18, 2025 | Franziska Michor director | AGrant or award Class A Common Stock | +22,016 | $0.00 | $0 | 127,053 | Jun 23, 2025 |
| Jun 18, 2025 | Elaine D Sun director | AGrant or award Class A Common Stock | +11,008 | $0.00 | $0 | 47,557 | Jun 23, 2025 |
| Jun 18, 2025 | Blake Borgeson director | AGrant or award Stock Option (Right to Buy)derivative | +44,031 | $0.00 | $0 | 44,031 | Jun 23, 2025 |
| Jun 18, 2025 | Namandje Bumpus director | AGrant or award Stock Option (Right to Buy)derivative | +22,016 | $0.00 | $0 | 22,016 | Jun 23, 2025 |
| Jun 18, 2025 | Zavain Dar director | AGrant or award Stock Option (Right to Buy)derivative | +44,031 | $0.00 | $0 | 44,031 | Jun 23, 2025 |
| Jun 18, 2025 | Robert Hershberg director | AGrant or award Stock Option (Right to Buy)derivative | +44,031 | $0.00 | $0 | 44,031 | Jun 23, 2025 |
| Jun 18, 2025 | Franziska Michor director | AGrant or award Stock Option (Right to Buy)derivative | +44,031 | $0.00 | $0 | 44,031 | Jun 23, 2025 |
| Jun 18, 2025 | Elaine D Sun director | AGrant or award Stock Option (Right to Buy)derivative | +22,016 | $0.00 | $0 | 22,016 | Jun 23, 2025 |
| Jun 18, 2025 | Dean Y Li director | AGrant or award Stock Option (Right to Buy)derivative | +44,031 | $0.00 | $0 | 44,031 | Jun 23, 2025 |
| Jun 16, 2025 | Ben R Taylor Chief Financial Officer | FTax withholding Class A Common Stock | -7,057 | $4.92 | $35k | 823,134 | Jun 18, 2025 |
| May 15, 2025 | Christopher Gibson Chief Executive Officer | FTax withholding Class A Common Stock | -36,197 | $4.25 | $154k | 1,081,253 | May 19, 2025 |
| May 15, 2025 | Najat Khan Chief R&D Commercial Officer | FTax withholding Class A Common Stock | -3,796 | $4.25 | $16k | 708,585 | May 19, 2025 |
| May 15, 2025 | Ben R Taylor Chief Financial Officer | FTax withholding Class A Common Stock | -11,908 | $4.25 | $51k | 830,191 | May 19, 2025 |
| Apr 1, 2025 | Zavain Dar director | AGrant or award Class A Common Stock | +2,745 | $0.00 | $0 | 110,877 | Apr 3, 2025 |
| Apr 1, 2025 | Dean Y Li director | AGrant or award Class A Common Stock | +2,268 | $0.00 | $0 | 79,618 | Apr 3, 2025 |
| Apr 1, 2025 | Ben R Taylor Chief Financial Officer | FTax withholding Class A Common Stock | -26,571 | $5.10 | $135k | 842,099 | Apr 3, 2025 |
| Mar 27, 2025 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stock10b5-1 | -138,574 | $6.04 | $837k | 1,117,450 | Mar 28, 2025 |
| Mar 17, 2025 | Namandje Bumpus director | AGrant or award Class A Common Stock | +36,549 | $0.00 | $0 | 36,549 | Mar 19, 2025 |
| Mar 17, 2025 | Namandje Bumpus director | AGrant or award Stock Option (Right to Buy)derivative | +73,099 | $0.00 | $0 | 73,099 | Mar 19, 2025 |
| Mar 5, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 1,276,024 | Mar 7, 2025 |
| Mar 5, 2025 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $6.58 | $132k | 1,256,024 | Mar 7, 2025 |
| Mar 6, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 1,276,024 | Mar 7, 2025 |
| Mar 6, 2025 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $6.37 | $127k | 1,256,024 | Mar 7, 2025 |
| Mar 5, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 5,916,700 | Mar 7, 2025 |
| Mar 6, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 5,896,700 | Mar 7, 2025 |
| Feb 18, 2025 | Christopher Gibson Chief Executive Officer | FTax withholding Class A Common Stock | -17,132 | $10.64 | $182k | 1,256,024 | Feb 20, 2025 |
| Feb 5, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 1,293,156 | Feb 7, 2025 |
| Feb 5, 2025 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $7.68 | $154k | 1,273,156 | Feb 7, 2025 |
| Feb 6, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 1,293,156 | Feb 7, 2025 |
| Feb 6, 2025 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $8.12 | $162k | 1,273,156 | Feb 7, 2025 |
| Feb 5, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 5,956,700 | Feb 7, 2025 |
| Feb 6, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 5,936,700 | Feb 7, 2025 |
| Feb 3, 2025 | Christopher Gibson Chief Executive Officer | AGrant or award Class A Common Stock | +525,283 | $0.00 | $0 | 1,261,916 | Feb 5, 2025 |
| Feb 3, 2025 | Najat Khan Chief R&D Commercial Officer | AGrant or award Class A Common Stock | +210,113 | $0.00 | $0 | 707,085 | Feb 5, 2025 |
| Feb 3, 2025 | Christopher Gibson Chief Executive Officer | AGrant or award Class A Common Stock | +16,809 | $0.00 | $0 | 1,278,725 | Feb 5, 2025 |
| Feb 3, 2025 | Najat Khan Chief R&D Commercial Officer | AGrant or award Class A Common Stock | +8,049 | $0.00 | $0 | 715,134 | Feb 5, 2025 |
| Feb 3, 2025 | Christopher Gibson Chief Executive Officer | FTax withholding Class A Common Stock | -5,569 | $7.25 | $40k | 1,273,156 | Feb 5, 2025 |
| Feb 3, 2025 | Najat Khan Chief R&D Commercial Officer | FTax withholding Class A Common Stock | -2,753 | $7.25 | $20k | 712,381 | Feb 5, 2025 |
| Feb 3, 2025 | Christopher Gibson Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +1,050,567 | $0.00 | $0 | 1,050,567 | Feb 5, 2025 |
| Feb 3, 2025 | Najat Khan Chief R&D Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +420,226 | $0.00 | $0 | 420,226 | Feb 5, 2025 |
| Jan 8, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 756,633 | Jan 13, 2025 |
| Jan 8, 2025 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $7.31 | $146k | 736,633 | Jan 13, 2025 |
| Jan 10, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 756,633 | Jan 13, 2025 |
| Jan 10, 2025 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $7.05 | $141k | 736,633 | Jan 13, 2025 |
| Jan 8, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 5,996,700 | Jan 13, 2025 |
| Jan 10, 2025 | Christopher Gibson Chief Executive Officer | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 5,976,700 | Jan 13, 2025 |
| Jan 2, 2025 | Blake Borgeson director | AGrant or award Class A Common Stock | +1,734 | $0.00 | $0 | 7,067,847 | Jan 6, 2025 |
| Jan 2, 2025 | Zavain Dar director | AGrant or award Class A Common Stock | +1,907 | $0.00 | $0 | 108,132 | Jan 6, 2025 |
| Dec 19, 2024 | Ben R Taylor Chief Financial Officer | AGrant or award Class A Common Stock | +370,343 | $0.00 | $0 | 844,210 | Dec 20, 2024 |
| Dec 19, 2024 | Ben R Taylor Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +740,686 | $0.00 | $0 | 740,686 | Dec 20, 2024 |
| Dec 16, 2024 | Ben R Taylor Chief Financial Officer | FTax withholding Class A Common Stock | -15,668 | $6.04 | $95k | 480,924 | Dec 18, 2024 |
| Dec 17, 2024 | Ben R Taylor Chief Financial Officer | FTax withholding Class A Common Stock | -7,057 | $6.95 | $49k | 473,867 | Dec 18, 2024 |
| Dec 4, 2024 | Christopher Gibson Chief Executive Officer | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 756,633 | Dec 6, 2024 |
| Dec 4, 2024 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $7.16 | $143k | 736,633 | Dec 6, 2024 |
| Dec 5, 2024 | Christopher Gibson Chief Executive Officer | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 756,633 | Dec 6, 2024 |
| Dec 5, 2024 | Christopher Gibson Chief Executive Officer | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $7.12 | $142k | 736,633 | Dec 6, 2024 |
| Dec 4, 2024 | Christopher Gibson Chief Executive Officer | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 6,036,700 | Dec 6, 2024 |
| Dec 5, 2024 | Christopher Gibson Chief Executive Officer | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 6,016,700 | Dec 6, 2024 |
| Nov 20, 2024 | Franziska Michor director | AGrant or award Class A Common Stock | +30,618 | - | - | 30,618 | Nov 22, 2024 |
| Nov 20, 2024 | Franziska Michor director | AGrant or award Class A Common Stock | +15,335 | $0.00 | $0 | 45,953 | Nov 22, 2024 |
| Nov 20, 2024 | Franziska Michor director | AGrant or award Class A Common Stock | +17,694 | $0.00 | $0 | 63,647 | Nov 22, 2024 |
| Nov 20, 2024 | Franziska Michor director | AGrant or award Class A Common Stock | +41,390 | $0.00 | $0 | 105,037 | Nov 22, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Blake Borgesondirector
- Namandje Bumpusdirector
- Zavain Dardirector
- Christopher GibsonChief Executive Officer
- Robert Hershbergdirector, officer, ceo, president
- Najat KhanChief R&D Commercial Officer
- Dean Y Lidirector, officer
- Tina MarriottPresident and COO
- Franziska Michordirector
- Michael SecoraChief Financial Officer
- Elaine D Sundirector
- Ben R TaylorChief Financial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.